ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 452

Features of Peripheral and Central Sensitization and Neuropathic Pain Are Seen in Both Osteoarthritis and Rheumatoid Arthritis

Jacquelin R. Chua1, Shingo Ishihara2, Mariam Riad1, Isabel Castrejón1, Rachel E. Miller3, Anne-Marie Malfait4, Joel A. Block1, Theodore Pincus1 and Najia Shakoor1, 1Division of Rheumatology, Rush University Medical Center, Chicago, IL, 2Internal Medicine, Rush University Medical Center, Chicago, IL, 3Biochemistry, Rush University Medical Center, Chicago, IL, 4Biochemistry & Rheumatology, Rush University Medical Center, Chicago, IL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: mechanisms, Osteoarthritis, pain and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Pain Mechanisms – Basic and Clinical Science Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

OA and RA are among the most common chronic painful rheumatic diseases. Appreciation of the role of pain sensitization in OA has revolutionized the management of chronic pain with neuroactive agents. By contrast, pain in RA has conventionally been considered to be “inflammatory”, with the belief that treatment with disease-modifying anti-rheumatic agents (DMARDs) aborts the painful experience. A number of patients with RA, however, continue to experience pain despite optimal control of inflammation. Thus, we aimed to test the hypothesis that pain in RA, similar to OA, includes signs of peripheral and central sensitization and neuropathic features.

Methods:

After consent, patients with physician diagnosis of symptomatic OA of the hips and/or knees (VAS pain score at the sites ≥3/10), active or DMARD-naïve RA (escalation or change in RA therapy, synovitis on physician exam at the reference clinic visit), and control (45 yrs or older, without pain ≥1 month, no arthritis or neuropathy or joint replacement history) were recruited and asked to fill a painDETECT (PD-Q) questionnaire 1. Quantitative sensory tests (QST) including pressure pain thresholds (PPT) using an algometer and temporal summation (TS) using von Frey monofilament (60 g), were performed on all subjects at right and left radial styloids, tibial tuberosities, and medial knees. Sensitization is present when there is low PPT using an algometer (peripheral= diseased site; central= no diseased site) and an increased in pain score after repeated controlled stimulation with von Frey monofilament (central) 2. Demographic data, PD-Q scores and results from QST were compared between groups using analysis of variance (ANOVA). PD-Q scores were classified as ≤12 -unlikely neuropathic vs >12 –likely neuropathic. Correlations between PD-Q scores and QST results were analyzed using Spearman’s rho.

Results:

Participants included 25 OA, 20 RA, and 19 controls. Patients with OA were older and had higher BMI than RA and control subjects (p <0.001). PD-Q scores were in the “likely neuropathic” range in 32% of OA and 40% of RA vs 0% of control subjects (p<0.001). Both OA and RA had lower PPT vs control at all tested sites. OA and RA patients exhibited significantly higher TS vs control subjects. PD-Q final score and component questions were associated significantly with PPT (rho=-0.244 to -0.448, p<0.05), but not to TS results.

Table: Demographic, clinical, and QST data of patients with symptomatic hip and/or knee OA, active or DMARD-naïve RA, and control subjects

Variable (s)

OA (n=25)

RA (n=20)

Control (n=19)

p all groups

Age

65.2 (10.2)

53.2 (10.7)

52.9 (10.4)

<0.001

BMI, kg/m2

32.8 (9.6)

25.9 (7.0)

26.6 (4.3)

0.007

%Female patients

88%

65%

58%

0.063

Pain detect final score

8.6 (6.4)

11.9 (9.2)

1.4 (2.5)

<0.001

Likely neuropathic, % patients

32%

40%

0%

0.009

PPT Left radial styloid, lbf

4.5 (2.7)

4.0 (1.5)

5.6 (2.6)

0.121

PPT Right radial styloid, lbf

4.5 (2.8)

3.6 (1.4)

5.6 (2.4)

0.037

PPT Left medial knee joint, lbf

4.6 (2.8)

4.4 (2.7)

7.7 (3.3)

0.001

PPT Right medial knee joint, lbf

4.5 (2.8)

4.1 (2.4)

7.7 (3.2)

<0.001

PPT Left tibial tuberosity, lbf

5.2 (2.9)

5.4 (2.5)

8.9 (2.8)

<0.001

PPT Right tibial tuberosity, lbf

6.1 (3.6)

5.0 (2.7)

11.1 (9.9)

0.005

TS left radial styloid, % patients

68.0%

75.0%

57.9%

0.385

TS right radial styloid, % patients

76.0%

85.0%

42.1%

0.009

TS left tibial tuberosity, % patients

76.0%

60.0%

26.3%

0.004

TS right tibial tuberosity, % patients

68.0%

85.0%

36.8%

0.006

Data are reported in mean (standard deviation) unless specified. Abbreviation: lbf, pound-force.

Conclusion:

Both OA and RA exhibited evidence of neuropathic features on a PD-Q questionnaire and peripheral and central sensitization on QST. To our knowledge, this is the first study evaluating sensitization in both OA and RA compared to control and demonstrating similar pain patterns and degrees of sensitization in both disease groups. The clinical and treatment implications of these findings warrant attention and further investigation.

Reference: 1. Curr Med Res Opin, Vol.22, No. 10 (2006); 2. Curr Osteoporosis Rep (2015).


Disclosure: J. R. Chua, None; S. Ishihara, None; M. Riad, None; I. Castrejón, None; R. E. Miller, None; A. M. Malfait, None; J. A. Block, Gilead, 1,Novartis, 2,Pfizer, Inc., 2,Janssen, 2,GlaxoSmithKline, 5,Zynerba Pharmaceuticals, 5,Agios, Inc, 7,Daiichi Sankyo, Inc., 7,Omeros, Inc., 7; T. Pincus, Medical History Services, LLC,, 7, 9; N. Shakoor, Dr. Comfort/DJO, 7.

To cite this abstract in AMA style:

Chua JR, Ishihara S, Riad M, Castrejón I, Miller RE, Malfait AM, Block JA, Pincus T, Shakoor N. Features of Peripheral and Central Sensitization and Neuropathic Pain Are Seen in Both Osteoarthritis and Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/features-of-peripheral-and-central-sensitization-and-neuropathic-pain-are-seen-in-both-osteoarthritis-and-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/features-of-peripheral-and-central-sensitization-and-neuropathic-pain-are-seen-in-both-osteoarthritis-and-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology